Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Philadelphia Chromosome

Lymphoma

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Lymphosarcoma

All Drugs and Chemicals

Anti-Inflammatory Agents

Antineoplastic Agents

Amino Acids

Antibodies

Antibodies, Monoclonal

Prednisone

Immunoglobulins

Blinatumomab

Dasatinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.

HLA typing will be performed immediately after the diagnosis for eligible patients.

MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation.

Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.

Upon induction:

patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary.

Paola Fazi

Enrico Crea

Piero Galieni

Nicola Cantore

Giorgina Specchia

Alessandro Rambaldi

Giovanni Martinelli

Angela Melpignano

Francesco Di Raimondo

Alberto Bosi

Angelo Michele Carella

Nicola Di Renzo

Renato Bassan

Agostino Cortelezzi

Valentina Mancini

Felicetto Ferrara

Delicetto Ferrara

Fabrizio Pane

Gianluca Gaidano

Giovanna Rege

Castello Califano

Francesco Fabbiano

Brunangelo Falini

Paolo Di Bartolomeo

Francesca Ronco

Anna Chierichini

Simona C Sica

Simona Sica

Adriano Venditti

Stefano C Mancini

Stefano Mancini

Roberto Foà

Sabina Chiaretti

Matteo Della Porta

Nicola Cascavilla

Ernesta Audisio

Alessandro Cignetti

Massimiliano Bonifacio

This study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of Blinatumomab, in adult Ph+ ALL.

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab

In particular, after 2 cycles of blinatumomab. Minimal Residual Disease (MRD) negativity is intended as Complete Molecular Remission (CMR)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia	NCT02744768	Acute Lymphobla...	Dasatinib Blinatumomab	18 Years -	Gruppo Italiano Malattie EMatologiche dell'Adulto
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia	NCT02744768	Acute Lymphobla...	Dasatinib Blinatumomab	18 Years -	Gruppo Italiano Malattie EMatologiche dell'Adulto

Spots Global Cancer Trial Database for acute lymphoblastic leukemia, adult, dasatinib, blinatumomab